Skip to main content
Clinical Trials/NCT03970187
NCT03970187
Completed
Not Applicable

Randomized Controlled Trial on the Efficacy of a VR Exposure-based Eye Contact Training‬ to Reduce Fear of Public Speaking

Prof. Dominique de Quervain, MD1 site in 1 country96 target enrollmentJune 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fear of Public Speaking (Subclinical)
Sponsor
Prof. Dominique de Quervain, MD
Enrollment
96
Locations
1
Primary Endpoint
Subjective Units of Distress Scale (SUDS, fear)
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Investigation of the efficacy of an eye contact training App in virtual reality, based on principles of exposure therapy for the treatment for subjects with fear of public speaking.

Detailed Description

The study will be conducted as a randomized controlled single-blind study in a parallel groups design. Participants will be divided into groups afraid of public speaking with and without fulfilling the criteria of social anxiety (according to DSM-V), which can represent a clinically relevant and more generalized form of public speaking anxiety. The treatment for the participants solely differs in terms of whether they receive (1) the VR exposure or (2) a fear-unrelated VR task (study phase 1) or no treatment at all (study phase 2), resulting in the following 2 groups: * Group 1 (treatment group) consists of individuals with fear of public speaking that will (in study phase 1) receive a three-session VR exposure and undergo (in study phase 2) a 2-week treatment period with the same VR scenarios, each repeated three times. * Group 2 (control group) consists of individuals with fear of public speaking that will not receive any active treatment but complete a distractor task in VR in study phase 1 and no treatment in study phase 2. In study phase 1, the treatment group receives three VR exposure sessions each lasting for 20 minutes, whereas the control group completes three virtual distractor tasks (e.g. virtual tours) of identical duration. In study phase 2, the treatment group completes a home training spanning two weeks (9 x 20-minutes sessions), whereas the control group does not receive any treatment (untreated comparison group). In study phase 1, before and after the virtual exposure session, participants undergo an in vivo PST to assess the acute effects of the VR exposure-based eye contact training App. In study phase 2, the participants undergo a third in vivo PST to assess the training effects of the VR exposure-based eye contact training after two weeks of home training. This design allows a direct isolation and comparison of acute effects (study phase 1) and of training effects (study phase 2) and therefore enables an overall estimation of the effectiveness of the VR exposure-based eye contact training. Approximately 96 participants between 18 and 40 years with fear of public speaking will take part in the study. Approximately 1 to 5 weeks after having finished the first study phase, all participants that have not dropped out will take part in the second study phase.

Registry
clinicaltrials.gov
Start Date
June 1, 2019
End Date
September 20, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Prof. Dominique de Quervain, MD
Responsible Party
Sponsor Investigator
Principal Investigator

Prof. Dominique de Quervain, MD

Director Division of Cognitive Neuroscience

University of Basel

Eligibility Criteria

Inclusion Criteria

  • Fear of public speaking, assessed by two separate aspects:
  • High fear in social situations including the potential of being evaluated by others
  • Social situations can only be withstood under high fear or are avoided
  • Aged between 18-40
  • Fluent in German

Exclusion Criteria

  • BDI-II sumscore \>= 20
  • Suicidal ideation (BDI-II item 9 \> 0)
  • Serious medical or psychological condition, other than social anxiety (including Depression, Epilepsy and Migraine)
  • Concurrent psychotherapy
  • Previous exposure-based therapy for social anxiety (including public speaking anxiety) or other anxiety disorders
  • Parallel participation in another psychological or medical study
  • Chronic medication intake (except oral contraceptives)
  • Chronic drug intake (i.e. LSD, mushrooms, Ecstasy, MDMA, amphetamines etc.)
  • Medication intake before visits (less than 24 h)
  • Alcohol intake before visits (less than 12 h)

Outcomes

Primary Outcomes

Subjective Units of Distress Scale (SUDS, fear)

Time Frame: Assessing change between baseline and predefined follow-up time points during 11 weeks

Fear of public speaking is quantified by means of SUDS-ratings during a Public Speaking Test (PST) in vivo.

Secondary Outcomes

  • Global external assessment of performance in an in vivo public speech test(Assessing change between baseline and predefined follow-up time points during 11 weeks)
  • Fear of eye contact (SUDS, eye contact)(Assessing change between baseline and predefined follow-up time points during 11 weeks)
  • Global self-assessment of performance in an in vivo public speech test(Assessing change between baseline and predefined follow-up time points during 11 weeks)
  • Global subjectively perceived improvement of fear, eye contact and performance after single VR-exposure/waitlist(Assessed at visit 1 after completing the second PST)
  • Global subjectively perceived improvement of fear, eye contact and performance after VR-training/waitlist(Assessed at visit 2 after completing the PST)
  • Physiological measures(Assessing change between baseline and predefined follow-up time points during 11 weeks)
  • Total time of eye contact during an in vivo public speech test(Assessing change between baseline and predefined follow-up time points during 11 weeks)
  • Questionnaire for social anxiety (Soziale-Phobie-Inventar; SPIN)(Assessing change between baseline and predefined follow-up time points during 11 weeks)
  • Questionnaire for fear of negative evaluation (The Furcht vor negativer Evaluation - Kurzskala; FNE-K)(Assessing change between baseline and predefined follow-up time points during 11 weeks)
  • Eye-tracking measures(Assessing change between baseline and predefined follow-up time points during 11 weeks)

Study Sites (1)

Loading locations...

Similar Trials